Skip to content

Defining and Treating Depression-related Asthma

Defining and Treating a New Pediatric Asthma Endotype: Depression-related Asthma Mediated by the Cholinergic Pathway

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04617015
Enrollment
39
Registered
2020-11-05
Start date
2016-09-09
Completion date
2019-03-11
Last updated
2026-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Childhood Asthma, Depression

Keywords

asthma, depression, anticholinergic therapy

Brief summary

Depression is seen more often in people with asthma, and may lead to increased development and severity of asthma. This study will investigate whether children with depression and asthma have less allergic disease and less inflammation than children with asthma who do not have symptoms of depression. The study will also investigate whether the lungs of children with depression and asthma respond to an anticholinergic inhaler called ipratropium more than the lungs of non-depressed asthmatic children.

Detailed description

It is well accepted that asthma is not a single uniform disease, but rather many different disease sub-entities with different etiologies and pathophysiologies. The term "endotype" was coined to delineate distinct subtypes of asthma; an "endotype" specifically is as "a subtype of a condition, which is defined by a distinct functional or pathophysiological mechanism". The division of asthma into endotypes is critical to the development of targeted immunomodulators and other specific treatment modalities to more effectively treat the diverse asthmatics encountered in clinical practice. There is a clear association between depression and asthma, with evidence suggesting that depression leads to increased development of asthma rather than the reverse. If, as suggested, depression truly mediates a subset of asthma, this depression-related asthma "endotype" has not been well characterized to date. A promising theory of the pathophysiological mechanism of depression-related asthma is that of autonomic nervous system dysregulation associated with depression leading to airway compromise (Miller and Wood, 2003). Specifically, depression is associated with excess parasympathetic (cholinergic) activation, and cholinergic activation can mediate bronchoconstriction through the action of acetylcholine on the muscarinic receptors on bronchial smooth muscle. It has been demonstrated that during emotional stimuli, depressed children with asthma have increased parasympathetic activation, which associates with increased airway resistance. In contrast, when experiencing these same emotional stimuli, non-depressed children with asthma have increased sympathetic activation. The investigators anticipate that depressed child asthmatics have cholinergically-mediated bronchoconstriction as a major mediator of their disease activity. Based upon studies of depressed asthmatic children showing increased parasympathetic/cholinergic reactivity in response to laboratory based emotional stimuli, along with a recent study showing that depressed asthmatic adults have decreased bronchodilatory response to beta-agonists, the investigators hypothesize that asthmatic children with higher depressive indices will have more bronchodilatory response on spirometry following treatment with a short-acting inhaled anticholinergic, and less additional bronchodilation with an inhaled beta-agonist, compared to children with lower depressive indices. The investigators will set out to demonstrate if during an episode of bronchoconstriction, depressed child asthmatics will achieve more bronchodilation from a short-acting inhaled anticholinergic than will non-depressed child asthmatics. The investigators next predict that with excess cholinergic activation as a cause of bronchoconstriction in depressed pediatric asthmatics, there will be less atopic sensitization and Th2-mediated inflammation driving the airway disease in this subset of asthmatics. The investigators hypothesize that, compared to non-depressed child asthmatics, depressed pediatric asthmatics during an episode of bronchoconstriction will show less evidence of airway inflammation as measured by fractional exhaled nitric oxide (FeNO) and peripheral blood eosinophilia, and will have lower rates of atopic sensitization measured by skin prick testing to environmental allergens and/or elevated total serum immunoglobulin E (IgE). In addition, the investigators will assess patient-identified asthma triggers, which are anticipated to be different in the depressed asthmatic group, with increased identification of emotions and cold weather as triggers, and less identification of allergens as triggers.

Interventions

DRUGIpratropium Bromide

All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.

Sponsors

State University of New York at Buffalo
Lead SponsorOTHER
National Center for Advancing Translational Sciences (NCATS)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Children with asthma and depression versus children with asthma without depression are compared for presence of allergies, airway inflammation, and response to bronchodilation with ipratropium.

Eligibility

Sex/Gender
ALL
Age
7 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of asthma * Decreased lung volumes for age/height/race (FEV1 \<80% predicted or ratio of FEV1 to forced vital capacity (FVC) \< 85%) on day of study visit assessed by spirometry.

Exclusion criteria

* Severely developmentally delayed patients, or those who suffer from other severe cognitive impairment not allowing them to perform spirometry or participate in study instruments. * Patients who are pregnant or nursing. * Patients with significant cardiopulmonary disease other than asthma, including cystic fibrosis, alpha-1-antitrypsin deficiency, interstitial lung disease, tracheo-/bronchomalacia, or cyanotic congenital cardiac defect. * Patients with glaucoma, myasthenia gravis, or bladder neck obstruction (anticholinergics can worsen these conditions). * Patients currently taking another anticholinergic medication

Design outcomes

Primary

MeasureTime frameDescription
FEV1 Percent Change Post-ipratropiumBaseline and 30 minutesdifference between lung function (FEV1) measurement from baseline to 30 minutes post ipratropium This measure was calculated using the formula: (Post-ipratropium value - baseline value) / baseline value x100

Secondary

MeasureTime frameDescription
FEV1 Percent Change Post-albuterol30 minutes and 45 minutesdifference between lung function (FEV1) measurement from post ipratropium to 15 minutes post-albuterol This measure was calculated using the formula: (Post-albuterol value - post-ipratropium value) / post-ipratropium value x100

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORHeather K Lehman, MD

SUNY at Buffalo School of Medicine and Biomedical Sciences

Participant flow

Pre-assignment details

All subjects enrolled received ipratropium bromide

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
39 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Age, Continuous12.92 years
STANDARD_DEVIATION 3.27
ATI Mood Score7.95 units on a scale
Blood eosinophils387.38 cells/mm^3
STANDARD_DEVIATION 298.15
Children's Depression Inventory T-score47 T-score
STANDARD_DEVIATION 9
Exhaled nitric oxide (FeNO)44.62 ppb
STANDARD_DEVIATION 48.8
FEV1 %predicted80.05 percent
STANDARD_DEVIATION 20.89
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
18 Participants
Race (NIH/OMB)
More than one race
2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
White
18 Participants
Serum Immunoglobulin E (IgE)613.6 UI/ml
STANDARD_DEVIATION 696.6
Sex: Female, Male
Female
19 Participants
Sex: Female, Male
Male
20 Participants
Specific allergen sensitization3.06 positive skin tests
STANDARD_DEVIATION 3.08

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 39
other
Total, other adverse events
0 / 39
serious
Total, serious adverse events
0 / 39

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 24, 2026